Related Experiment Video
Updated: Jun 13, 2025
Microsurgical Skills of Establishing Permanent Jugular Vein Cannulation in Rats for Serial Blood Sampling of Orally Administered Drug
Published on: December 14, 2021
The Impact of Hyperuricemia on Pharmacokinetics in Sprague-Dawley Rats
Xiaomeng Pan1, Dandan Li1, Yujuan Chen1
1College of Pharmacy, Hebei Medical University, 361 East Zhongshan Road, Shijiazhuang, 050017, Hebei, China.
Background And Objective:
Hyperuricemia (HUA) is a metabolic disease closely associated with hypertension. It can induce liver damage, subsequently affecting drug metabolism. However, its specific impacts and underlying mechanisms remain unclear. Therefore, the pharmacokinetics and cytochrome P450 (CYP450) enzyme activities were investigated.
Methods:
Twelve healthy Sprague-Dawley rats were randomly assigned into two groups, a control group and an experimental group, with six animals per group. To establish the HUA model, rats in the experimental group received a subcutaneous injection of potassium oxonate (POx) (250 mg/kg), combined with oral administration of a fructose solution (5%, w/v). Serum biochemical parameters were subsequently evaluated, while histopathological examinations of liver and kidney tissues were performed. Plasma amlodipine (ALDP) levels were quantified by employing LC-MS/MS, and pharmacokinetic parameters were analyzed using DAS 3.0 software. Furthermore, activities of six major CYP450 enzyme isoforms were simultaneously determined through the cocktail method.
Results:
In the HUA-induced rats, significant elevations in serum uric acid (SUA), blood urea nitrogen (BUN), and creatinine (Cr) were observed, accompanied by distinct pathological lesions within hepatic and renal tissues. Pharmacokinetic analyses demonstrated marked increases in the peak plasma concentration (Cmax), terminal elimination half-life (t½), and time to reach peak concentration (Tmax) of ALDP, which were elevated by approximately 2.7-fold, 1.5-fold, and 2.1-fold, respectively. The apparent oral clearance (CLz/F) significantly decreased by half. Furthermore, the activities of six CYP450 enzymes notably decreased: CYP2E1 by 94%, CYP2C19 by 92%, CYP2C9 by 91%, CYP2D6 by 80%, CYP3A1 by 73%, and CYP1A2 by 7%.
Conclusion:
This study successfully established a stable rat model of HUA, and demonstrated that HUA specifically alters drug metabolism by causing liver damage and modulating CYP450 enzyme activities.
More Related Videos
Related Concept Videos
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:09Factors Affecting Renal Clearance: Drug Distribution and Drug Interactions
One important factor is the relationship between renal clearance and the apparent volume of distribution. Renal clearance tends to be inversely proportional to the apparent volume of distribution. Drugs with an extensive distribution volume or those...
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
01:31Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
01:19Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...